Argos Awarded $21M to Develop its Personalized HIV Therapy
Grant to help determine immunogenicity of the immunotherapy.!--h2>
Argos Therapeutics has been awarded a five-year, $21-million NIH contract to develop HIV immunotherapy candidates. Argos is developing personalized, RNA-loaded dendritic cell immunotherapy products designed to train the patient’s immune system to recognize, target, and destroy unique features of their disease.
The goal of the contract, issued by the NIAID, is to determine the immunogenicity of Argos’ HIV immunotherapy candidate currently in clinical trials and subsequently develop more potent product candidates.
Argos has partnered with a number of leading institutions which will participate in the development program. The award will cover substantially all costs associated with the development of such HIV immunotherapies, as well as portions of costs related to Argos’ current HIV candidate development.